Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

On Wednesday, GH Research announced that FDA is retaining a clinical hold on its Investigational New Drug (IND) application to commence a trial of its inhaled 5-MeO-DMT candidate (GH001) for treatment-resistant depression (TRD) in the U.S. That hold was first revealed nearly two years ago, in September 2023. Last month, the company announced that it had submitted a complete response to…

Source